Skip to main content

Table 3 Treatment outcome to afatinib and resistance mechanism identified at disease progression

From: Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Treatment outcome Total number of patients
(n = 85)
Best tumor response, No. (%)
 Complete response 2 (2.4)
 Partial response 63 (74.1)
 Stable disease 16 (18.8)
 Progressive disease 4 (4.7)
Disease progression site, No. (%)
 None 29 (34.1)
 New brain lesions 7 (8.2)
 New lesions at other sites 49 (57.6)
Investigation for resistance mechanism, No. (%)
 No progression 29 (34.1)
 Not investigated 25 (29.4)
 Investigated 31 (36.5)
  -Exon 20 T790 M mutation detected 13 (42.0)
  -Exon 20 T790 M mutation not detected and no histologic transformation 18 (58.0)